| PHARVARIS N.V. EO -,12 |
| Niederlande |
| Gesundheit |
| NL00150005Y4 / A2QNWS |
| 9EN (Frankfurt) / PHVS (NASDAQ) |
| FRA:9EN, ETR:9EN, 9EN:GR, NASDAQ:PHVS |
| - |
| https://pharvaris.com/ |
|
Pharvaris N.V. Ordinary Shares represent the equity of Pharvaris N.V., a late-stage biopharmaceutical company focused on developing oral therapies for rare bradykinin-mediated diseases. The company’s core work centers on bradykinin B2 receptor anta..
>Volltext.. |
| 2120.77 Mio. EUR |
| 1802.55 Mio. EUR |
| - |
| -182.59 Mio. EUR |
| -171.62 Mio. EUR |
| -2.63 EUR |
| 0.66 Mio. EUR |
| 313.37 Mio. EUR |
| -157.26 Mio. EUR |
| 11.63 |
| - |
| -12.19% |
| - |
| - |
| - |
| PHARVARIS |
| 08.09.26 |